<DOC>
	<DOCNO>NCT01404000</DOCNO>
	<brief_summary>The purpose study determine whether treatment Iodinated Active Charcoal improve lung function physical capacity patient chronic obstructive lung disorder . The rational study observation COPD patient increase tissue load mercury interfere function NeuroEpithelial Endocrine ( NEE ) cell respiratory tract . Mercury bind NEE cell lead increase smooth muscle tonus reduce response bronchodilator treatment . Initial observational data show improved lung function improve functional capacity treatment motivate large placebo control POC study</brief_summary>
	<brief_title>Treatment Chronic Obstructive Pulmonary Disease ( COPD ) With Iodinated Activated Charcoal</brief_title>
	<detailed_description />
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Charcoal</mesh_term>
	<criteria>Male &gt; 1 year postmenopausal , surgically sterile female . 4580 year old . Smokers exsmokers , least 15 pack year . COPD accord GOLD II . FEV % &lt; 70 Post beta2agonist FEV1 &gt; 50 &lt; 80 % predict value CO diffusion capacity &lt; 75 % . Active symptomatic COPD COPD assessment test ( CAT ) score &gt; 10 . Alpha1 antitrypsin deficiency Iodine allergy Abnormal thyroid function Severely reduce kidney function ( Cystatin C &gt; 1.5 mg/L . Exacerbation within 4 week prior study . Use per oral steroid within 4 week prior study . Alcohol/drug abuse . Psychiatric disease . Severe cardiovascular severe disease , accord clinical investigator . Oxygen treatment . Participation another ongoing clinical trial participation drug</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>